Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

I thought his change was because Momenta was changing its business model to chase Bio-similar's instead of complex generics. He makes the point that their run rate is excessive.

In hindsight, Momenta's burn rate is way too high to afford this type of direction change. All said and done I'm not sure Momenta will ever make a penny off of Lovenox or Copaxone if you consider their lifelong investment.